日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study

卡培他滨治疗患者的DPYD基因分型:来自D-TORCH研究的探索性分析

Baskarane, Hemavathi; Divakar, Mohit Kumar; Santhosh, Akhil P; Pallavi, Kriti; Hooda, Vishakha; Yenamandra, Vamsi Krishna; Kumar, Saran; Shetty, Vrajesh; Banotra, Jahnavi; Gupta, Ishaan; Minocha, Shilpi; Tanwar, Pranay; Sharma, Atul; Vasudeva, Payal; Kumar, Akash; Chethan, R; Bakhshi, Sameer; Batra, Atul

Genetic Variants Associated with Fluoropyrimidine-Induced Toxicity in Real-World Patients After Pre-Emptive DPYD Pharmacogenetic Testing

预防性DPYD药物遗传学检测后,真实世界患者中与氟嘧啶类药物诱导毒性相关的遗传变异

Rodríguez-García, María; Salvador-Martín, Sara; Rojas Piedra, Mariam Stephanie; Bravo, Adrián; Vidal, María; Figueras Gutierrez, Carolina; Maurel, Joan; López-Fernández, Luis A; Brunet, Mercè

Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy

社会经济因素是否会影响DPYD检测?一项针对1478名接受氟尿嘧啶化疗的癌症患者的真实世界研究

Baraka, Bahaaeldin; Mathiyalagan, Navin; Al-Ani, Maryam; Mohindru, Gaurav; Semple, Torran; Divyateja, Hrushikesh; Figueredo, Grazziela; Quinlan, Philip; Aithal, Guruprasad Padur; Madhusudan, Srinivasan

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider

意大利DPYD和UGT1A1检测的普及率及药物遗传学指南的遵循情况:来自外部质量评估机构的五年视角

Roncato, Rossana; Perfler, Samantha; Pasin, Diletta; Peruzzi, Elena; Woodcock, Michael; Thomas, Henry; Goodall, Rebecca; Patton, Simon J; Cecchin, Erika

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer

卡培他滨治疗转移性乳腺癌前进行DPYD基因分型的成本效益分析

Chiddarwar, Tanvi; Blaes, Anne; Kuntz, Karen

Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy

全球范围内对DPYD检测临床实施策略的研究,旨在指导氟尿嘧啶类药物治疗。

El Rouby, Nihal; Aquilante, Christina L; Bargal, Salma A; Cavallari, Larisa H; Duarte, Julio D; Gunderson, Kelly; Mazhindu, Tinashe; Nagy, Mohamed; Nie, Xiaoyan; Nguyen, D Grace; Patel, Jai N; Skaar, Todd C; Smith, D Max; Tuteja, Sony; van Schaik, Ron H N; Hicks, J Kevin

Integrated analysis of metabolic gene features and the immune microenvironment: identification of DPYD-mediated prognostic model and therapeutic targets in pancreatic cancer

代谢基因特征与免疫微环境的整合分析:DPYD介导的胰腺癌预后模型及治疗靶点的鉴定

Bao, Haoyu; Pu, Bowen; Zhu, Shengpeng; Chen, Yongqiang; Wang, Xiaohong; Guo, Weihao; Sun, Qikai; Qian, Yeben

Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes

癌症患者二氢嘧啶脱氢酶 (DPYD) 基因检测及 5-氟嘧啶类药物治疗:活性降低变异体的患病率及化疗疗效

Rosso, Christopher; Febbraro, Michela; Voutsadakis, Ioannis A

The Path to Clinical Implementation of <italic>DPYD</italic> Pharmacogenetic Testing: Long-Term Experience from an External Quality Assessment Provider and a University Testing Center

DPYD药物基因组学检测临床应用之路:来自外部质量评估机构和大学检测中心的长期经验

Hedtke, Maren; Ast, Volker; Leidheiser, Johannes; Kessler, Anja; Neumaier, Michael; Hofheinz, Ralf-Dieter; Haselmann, Verena

Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population

巴西肿瘤患者DPYD和UGT1A1基因分型:在混合人群中应用药物基因组学

Cereser, Vinicius Humberto Bandeira; Moniz, Camila Motta Venchiarutti; Suarez-Kurtz, Guilherme; Estevez-Diz, Maria Del Pilar